Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of adding alginate–antacid chewable tablet to proton pump inhibitor in refractory gastroesophageal reflux disease
IRCT20230629058615N8Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of Gaviscon in gastroesophageal reflux disease (GERD), sponsored by Islamic Azad University. Started May 2025; status: completed.
02
Drugs
Gaviscon
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on IRCT20230629058615N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230629058615N8.